US Depression/Major Depressive Disorders (MDD) Market Analysis

US Depression/Major Depressive Disorders (MDD) Market Analysis


$ 3999

US Depression/Major Depressive Disorders (MDD) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Factors driving the Depression/Major Depressive Disorders (MDD) market include rising global depression prevalence, increased awareness and understanding of mental health issues, advancements in treatment options such as new medications and therapies, rising healthcare expenditure and insurance coverage for mental health, and government initiatives aimed at improving mental healthcare access. Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, H. Lundbeck A/S, Merck & Co., Inc., Allergan plc are global key players in Depression/Major Depressive Disorders (MDD) Market.

ID: IN10USPH269 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Dr. Medha Sansanwal

Buy Now

US Depression/Major Depressive Disorders (MDD) Market Analysis Summary

US Depression/Major Depressive Disorders (MDD) Market is valued at around $3239.1 Mn in 2022 and is projected to reach $3968.1 Mn by 2030, exhibiting a CAGR of 2.57% during the forecast period 2023-2030.

Factors driving the Depression/Major Depressive Disorders (MDD) market include rising global depression prevalence, increased awareness, and understanding of mental health issues, advancements in treatment options such as new medications and therapies, rising healthcare expenditure and insurance coverage for mental health, and government initiatives aimed at improving mental healthcare access. These drivers collectively contribute to the expansion of the market and the demand for effective treatments for depression and MDD. Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, H. Lundbeck A/S, Merck & Co., Inc., Allergan plc are global key players in Depression/Major Depressive Disorders (MDD) Market.

Market Dynamics

Market Growth Drivers

  1. Increasing Prevalence: The rising global prevalence of depression and major depressive disorders is a significant market driver, with more people seeking diagnosis and treatment
  2. Raising Knowledge: Raising awareness and understanding of mental health conditions, such as depression, has resulted in increased acknowledgment and reduced stigma, boosting demand for treatments
  3. Treatment Advances: Ongoing research and development of novel antidepressant drugs and therapy techniques provide better options for depression management, driving market growth
  4. Rising Healthcare Expenditure: Rising healthcare spending and insurance coverage for mental health issues help to drive market growth
  5. Government Activities: Government initiatives to improve access to mental healthcare, fund research, and enact mental health legislation encourage market growth

Market Restraints

  1. Stigma and Mental Health Awareness: The persistent stigma associated with mental health may dissuade people from seeking treatment, resulting in underdiagnosis and undertreatment
  2. Treatment Efficacy Is Limited: The varied response to antidepressant drugs and therapy makes it difficult to achieve consistent and satisfactory treatment outcomes. Antidepressant drugs may cause side effects, and worries regarding their safety and long-term effects can affect patient adherence and acceptance
  3. Access to Mental Health Services: The scarcity of mental health services, including specialized personnel and facilities, impedes prompt and proper treatment
  4. Affordability and Insurance Coverage: The cost of treatment, along with inadequate mental health insurance coverage, can limit access to effective interventions

Competitive Landscape

Key Players

  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Bristol Myers Squibb Company
  • H. Lundbeck A/S
  • Merck & Co., Inc.
  • Allergan plc

Developments in Depression/Major Depressive Disorders (MDD) Market

  • Usona Institute is evaluating the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in a Phase II clinical study.
  • Ketamine was approved by the FDA as a sedative/analgesic and general anesthetic is now found effective in treating severe depression says the Harvard Gazette in 2023.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Depression/Major Depressive Disorders (MDD) Market Segmentation

By Drug Class

  • SSRIs
  • SNRIs
  • Tricyclic Antidepressants (TCAs)
  • Atypical Antidepressants
  • Others

By Therapy Type

  • Cognitive Behavioural Therapy (CBT) 
  • Psychodynamic Therapy
  • Interpersonal Therapy (IPT)
  • Others

By End User

  • Hospitals
  • Clinics
  • Specialized Mental Health Centres
  • Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up